Patents by Inventor Lee Lim

Lee Lim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12559799
    Abstract: The present invention includes compositions and methods useful for the detection of a mutational change, SNP, translocation, inversion, deletion, change in copy number, or other genetic variation within a sample of cellular genomic DNA or cell-free DNA (cfDNA). In some embodiments, the compositions and methods of the present invention provide an extremely high level of resolution that is particularly useful in detecting copy number variations in a small fraction of the total cfDNA from a biological sample (e.g., blood).
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: February 24, 2026
    Assignee: Resolution Bioscience, Inc.
    Inventors: Christopher Raymond, Lee Lim, Jennifer Hernandez
  • Publication number: 20240191293
    Abstract: The disclosure provides compositions and methods that combine the benefits of different genetic analysis methods by performing simultaneous genetic analysis on a single pool of different libraries that were generated for different approaches, such as a combined library comprising a LPWG library and a target-enriched library.
    Type: Application
    Filed: March 30, 2022
    Publication date: June 13, 2024
    Inventors: Jiannan Guo, Carolyn Hutcheon, Mark Li, Lee Lim, Ira Pekker, Chen-Hsun Tsai
  • Publication number: 20220325353
    Abstract: The present invention includes compositions and methods useful for the detection of a mutational change. SNP, translocation, inversion, deletion, change in copy number, or other genetic variation within a sample of cellular genomic DNA or cell-free DNA (cfDNA). In some embodiments, the compositions and methods of the present invention provide an extremely high level of resolution that is particularly useful in detecting copy number variations in a small fraction of the total cfDNA from a biological sample (e.g., blood).
    Type: Application
    Filed: January 27, 2022
    Publication date: October 13, 2022
    Inventors: Christopher RAYMOND, Lee LIM, Jennifer HERNANDEZ
  • Publication number: 20220267763
    Abstract: The invention provides a method for efficient DNA library construction and targeted genetic analyses of the libraries.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 25, 2022
    Inventors: Christopher RAYMOND, Lee LIM
  • Patent number: 11319594
    Abstract: The present invention includes compositions and methods useful for the detection of a mutational change, SNP, translocation, inversion, deletion, change in copy number, or other genetic variation within a sample of cellular genomic DNA or cell-free DNA (cfDNA). In some embodiments, the compositions and methods of the present invention provide an extremely high level of resolution that is particularly useful in detecting copy number variations in a small fraction of the total cfDNA from a biological sample (e.g., blood).
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: May 3, 2022
    Assignee: Resolution Bioscience, Inc.
    Inventors: Christopher Raymond, Lee Lim, Jennifer Hernandez
  • Patent number: 10584335
    Abstract: The instant disclosure features single-stranded RNA molecules comprising one or more internal, non-nucleotide spacers. A non-nucleotide spacer covalently links nucleotide portions of the molecule. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism and, thus, represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: March 10, 2020
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
  • Patent number: 10526602
    Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: January 7, 2020
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
  • Publication number: 20180163272
    Abstract: The present invention includes compositions and methods useful for the detection of a mutational change, SNP, translocation, inversion, deletion, change in copy number, or other genetic variation within a sample of cellular genomic DNA or cell-free DNA (cfDNA). In some embodiments, the compositions and methods of the present invention provide an extremely high level of resolution that is particularly useful in detecting copy number variations in a small fraction of the total cfDNA from a biological sample (e.g., blood).
    Type: Application
    Filed: August 24, 2017
    Publication date: June 14, 2018
    Inventors: Christopher Raymond, Lee Lim, Jennifer Hernandez
  • Publication number: 20180112216
    Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.
    Type: Application
    Filed: July 12, 2017
    Publication date: April 26, 2018
    Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
  • Publication number: 20180080024
    Abstract: The instant disclosure features single-stranded RNA molecules comprising one or more internal, non-nucleotide spacers. A non-nucleotide spacer covalently links nucleotide portions of the molecule. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism and, thus, represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.
    Type: Application
    Filed: November 10, 2017
    Publication date: March 22, 2018
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
  • Patent number: 9845466
    Abstract: Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: December 19, 2017
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
  • Patent number: 9732342
    Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: August 15, 2017
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
  • Publication number: 20160222381
    Abstract: Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.
    Type: Application
    Filed: December 14, 2015
    Publication date: August 4, 2016
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
  • Patent number: 9243246
    Abstract: Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: January 26, 2016
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Lee Lim, Guillaume Chorn, Aarron Willingham, Lihong Zhao
  • Publication number: 20150376613
    Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.
    Type: Application
    Filed: June 23, 2015
    Publication date: December 31, 2015
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
  • Patent number: 9200275
    Abstract: In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence comprises a seed region consisting of nucleotide positions 1 to 12, wherein position 1 represents the 5? end of the iRNA nucleotide sequence and wherein said seed region comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to six contiguous nucleotides within positions 1 to 12 of a nucleotide sequence, wherein position 1 represents the 5?end of the nucleotide sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: December 1, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter S. Linsley, Janell Schelter, Julja Burchard, Lee Lim, Miho Kibukawa
  • Patent number: 9096850
    Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: August 4, 2015
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
  • Publication number: 20130225652
    Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.
    Type: Application
    Filed: August 24, 2010
    Publication date: August 29, 2013
    Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
  • Publication number: 20130171242
    Abstract: Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.
    Type: Application
    Filed: August 19, 2011
    Publication date: July 4, 2013
    Inventors: Lee Lim, Guillaume Chorn, Aarron Willingham, Lihong Zhao
  • Publication number: 20110111976
    Abstract: One aspect of the invention generally relates to use of tissue enriched miRNAs as biomarker to estimate tissue damage in a fluid sample. In a second aspect, methods are provided for monitoring a subject who is exposed or might have been exposed to an agent that has a risk of causing tissue injury. In a third aspect, methods are provided for identifying an agent as having a risk of causing tissue injury to a vertebrate subject. In a fourth aspect, kits are provided for practicing the methods of above-listed aspects. The contents of this ABSTRACT are not intended to in anyway limit the scope of the inventions claimed herein.
    Type: Application
    Filed: April 24, 2009
    Publication date: May 12, 2011
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Thomas L. Fare, Philip W. Garrett-Engele, Warren E. Glaab, Jason M. Johnson, Omar F. Laterza, Lee Lim, Steve W. Ludmerer, David B. Olsen, Joseph F. Sina, Frank D. Sistare